Most people wouldn’t know that we are the only country in the world allowing imported medical cannabis products into Australia that do not meet Good Manufacturing Practice (GMP) international standards.

Based on the huge increase in SAS-B products available, there is a real risk of inferior products adversely affecting patients.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Cymra Life Sciences co-founder Joel Hardy

The current system also negatively impacts local manufacturers who have to comply with GMP rules, which adds costs and gives importers an unfair advantage.

Prior to launching Cannabiz, Martin was co-founder and CEO of Asia-Pac’s leading B2B media and marketing information brand Mumbrella, overseeing its sale to Diversified Communications in 2017. A journalist...